Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN   3:59:58 PM EDT
618.68
-20.22 (-3.16%)
Products, Other Pre-Announcement

Regeneron Announces New U.S. Government Agreement To Purchase Additional Doses Of Regen-Cov Antibody Cocktail

Published: 09/14/2021 21:42 GMT
Regeneron Pharmaceuticals, Inc. (REGN) - Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of Regen-cov™ (casirivimab and Imdevimab) Antibody Cocktail.
Regeneron Pharmaceuticals Inc - New Agreement for 1.4 Million Doses of Regen-cov, Brings Total Purchased by U.S. Government to Nearly 3 Million Doses.
Regeneron Pharmaceuticals Inc - Government Will Continue to Provide Regen-cov at No Cost to Patients.
Regeneron - Will Supply an Additional 1.4 Million 1,200 Mg Doses of Regen-cov to U.S. Government by January 31, 2022, at a Cost of $2,100 per Dose.
Regeneron Pharmaceuticals - Expects to Begin Delivering Additional Regen-cov Doses to U.S. Government in September, With Vast Majority Delivered in Q4 2021.